Carbogen Amcis buys French CRO
pharmafile | January 23, 2012 | News story | Manufacturing and Production | Carbogen Amcis, Creapharm Parenterals
Swiss contract manufacturing organisation Carbogen Amcis has acquired a contract manufacturer based in France – Creapharm Parenterals – to bolster its ability to supply sterile injectable products.
Terms of the acquisition were not disclosed, but Carbogen Amcis said the addition of Creapharm Parenterals would expand its development and manufacturing portfolio by adding additional formulation and lyophilisation services, as well as sterile, GMP-grade manufacturing capabilities for a range of compounds such as highly potent active pharmaceutical ingredients (HPAPIs)
The acquisition would boost Carbogen Amcis’ ability to supply compounds for pre-clinical studies and clinical trials, said its parent company Dishman Pharmaceuticals & Chemicals of India, which acquired the Swiss unit in 2006.
Dishman’s chief financial officer V.V.S. Murthy told Reuters that adding Creapharm Parenterals to its portfolio would boost sales in the order of 130-140 million rupees (around $3 million) in the first 12 months.
Last year, Carbogen Amcis restructured its Swiss manufacturing operations because of what it described as ‘inadequate profitability’, shedding around 60 staff out of its total workforce of 350.
As a result of the revamp the firm’s site in Aarau now focuses more strongly on development services, Hunzenschwil concentrates on pilot production of early phase projects, while large-volume production is carried out at Bubendorf.
As a whole the Dishman group posted a net loss of 63 million rupees in the third quarter of 2011, in part due to adverse exchange rate effects such as the decline in value of the rupee compared to the US dollar, but also on the back of slowing revenue growth. Carbogen Amcis accounts for around 50% of the company’s total contract research and manufacturing service sales.
Dishman divestment
Meanwhile Dishman is in talks with potential buyers for a manufacturing facility in Shanghai, China, which produces APIs and pharmaceutical intermediates for customers in the US and Europe. The Indian company has reportedly invested $20 million in the facility ad is looking for a sale price of around $25 million.
Phil Taylor
Related Content
Pharma manufacturing news in brief
Facility updates from Bristol-Myers Squibb, WuXi PharmaTech, Quotient Clinical, CSM GlobalPharma and SCM Pharma, plus …
Carbogen Amcis opens large-scale high-potency API plant
Carbogen Amcis, the Swiss subsidiary of Dishman Pharmaceuticals and Chemicals of India, has opened a …
